{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343446","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2026-08-11T11:35:09+00:00","discovered_at":"2026-08-11T11:40:00.297379+00:00","generated_at":"2026-08-11T11:40:17.149392+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sagimet posts Q2 2026 net loss of $14.0M; $257.6M cash funds operations through 2028","bullets":["Q2 2026 net loss $14.0M vs $10.4M in Q2 2025; H1 2026 net loss $24.6M vs $28.6M.","Cash, equivalents and marketable securities $257.6M as of June 30, 2026, expected to fund operations through 2028.","Phase 3 trial of denifanstat in moderate to severe acne on track to initiate in U.S. in H2 2026.","Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned before end of 2026.","Completed $175.0M equity financing in April 2026; added to Russell 3000 and Russell 2000 indexes in June."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343446","json":"https://secwatch.observer/filing/0001193125-26-343446.json","markdown":"https://secwatch.observer/filing/0001193125-26-343446.md","text":"https://secwatch.observer/filing/0001193125-26-343446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/0001193125-26-343446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:40:17.149392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}